Comments
Loading...
Rapport Therapeutics Analyst Ratings and Price Targets | NASDAQ:RAPP | Benzinga
Rapport Therapeutics Inc has a consensus price target of $35 based on the ratings of 5 analysts. The high is $42 issued by Jones Trading on October 18, 2024. The low is $28 issued by JMP Securities on April 8, 2025. The 3 most-recent analyst ratings were released by JMP Securities, Jones Trading, and Stifel on April 8, 2025, October 18, 2024, and July 2, 2024, respectively. With an average price target of $35 between JMP Securities, Jones Trading, and Stifel, there's an implied 205.94% upside for Rapport Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Jones Trading
Stifel
Jefferies
1calculated from analyst ratings
Analyst Ratings for Rapport Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 144.76% | JMP Securities | Jason Butler51% | → $28 | Initiates | → Market Outperform | Get Alert |
| 10/18/2024 | Buy Now | 267.13% | Jones Trading | Justin Walsh41% | → $42 | Initiates | → Buy | Get Alert |
| 07/02/2024 | Buy Now | 205.94% | Stifel | Paul Matteis44% | → $35 | Initiates | → Buy | Get Alert |
| 07/02/2024 | Buy Now | — | TD Cowen | Joseph Thome26% | — | Initiates | → Buy | Get Alert |
| 07/02/2024 | Buy Now | 205.94% | Jefferies | Andrew Tsai28% | → $35 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Rapport Therapeutics (RAPP) stock?
The latest price target for Rapport Therapeutics (NASDAQ:RAPP) was reported by JMP Securities on April 8, 2025. The analyst firm set a price target for $28.00 expecting RAPP to rise to within 12 months (a possible 144.76% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rapport Therapeutics (RAPP)?
The latest analyst rating for Rapport Therapeutics (NASDAQ:RAPP) was provided by JMP Securities, and Rapport Therapeutics initiated their market outperform rating.
When was the last upgrade for Rapport Therapeutics (RAPP)?
There is no last upgrade for Rapport Therapeutics
When was the last downgrade for Rapport Therapeutics (RAPP)?
There is no last downgrade for Rapport Therapeutics.
When is the next analyst rating going to be posted or updated for Rapport Therapeutics (RAPP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapport Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapport Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Rapport Therapeutics (RAPP) correct?
While ratings are subjective and will change, the latest Rapport Therapeutics (RAPP) rating was a initiated with a price target of $0.00 to $28.00. The current price Rapport Therapeutics (RAPP) is trading at is $11.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
